SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-083210
Filing Date
2020-03-24
Accepted
2020-03-24 08:01:10
Documents
12
Period of Report
2020-03-23
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d903016d8k.htm   iXBRL 8-K 30462
  Complete submission text file 0001193125-20-083210.txt   154429

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20200323.xsd EX-101.SCH 3052
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20200323_lab.xml EX-101.LAB 18139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20200323_pre.xml EX-101.PRE 11396
13 EXTRACTED XBRL INSTANCE DOCUMENT d903016d8k_htm.xml XML 3376
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 20736638
SIC: 2834 Pharmaceutical Preparations